GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹457 Cr | ₹489 Cr | ₹90 Cr | ₹94 Cr | ₹80 Cr |
What is the latest Total Non-Current Liabilities ratio of GLAND PHARMA ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹457 Cr |
| Mar2024 | ₹489 Cr |
| Mar2023 | ₹90 Cr |
| Mar2022 | ₹94 Cr |
| Mar2021 | ₹80 Cr |
How is Total Non-Current Liabilities of GLAND PHARMA Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹457 Cr | -6.41 | |
| Mar2024 | ₹489 Cr | 444.83 | |
| Mar2023 | ₹90 Cr | -4.57 | |
| Mar2022 | ₹94 Cr | 17.01 | |
| Mar2021 | ₹80 Cr | - | |
Compare Total Non-Current Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹41,495.0 Cr | 5.7% | 2.1% | 24.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹480,047.0 Cr | 3.1% | 7.2% | 18.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹208,141.0 Cr | 8.2% | 19.8% | 17.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,264.0 Cr | -1.8% | 4.9% | 37.2% | Stock Analytics | |
| CIPLA | ₹118,430.0 Cr | 3.9% | 0.6% | 0% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,516.1 Cr | -0.7% | -14.6% | -8.4% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 5.7% |
2.1% |
24.8% |
| SENSEX | 2% |
1.9% |
-5.2% |
You may also like the below Video Courses